TNF and rheumatoid arthritis: An open-label uncontrolled study of rituximab (100 mg on week 1, 375 mg/m2 on week 2, 500 mg/m2 on week 3 and 4) in 13 RA patients, 6 of whom were refractory to anti-TNFα, showed that two third of patients achieved the ACR20 response at week 28 [15].